乾癬治療市場：薬剤タイプ別、投与経路別、疾患タイプ別、エンドユーザー別、流通チャネル別 - 2025年～2030年の世界予測

乾癬治療市場は、2024年に195億4,000万米ドルとなり、2025年には211億9,000万米ドルで、CAGR8.71%で成長し、2030年までには322億6,000万米ドルに達すると予測されています。

治療オプションの進化と患者の転帰を形成する規制力学の中で乾癬治療パラダイムを理解する

乾癬治療の複雑性を理解することは、進化する治療プラットフォームと規制の枠組みが世界的に患者治療を再構築する中で不可欠です。乾癬は慢性的な疾患であるため、身体的不快感や心理社会的負担が大きく、より効果的で的を絞った治療法の開発が急務となっています。これに対し、製薬企業やバイオテクノロジーのイノベーターは、有効性の向上、安全性プロファイルの改善、個別化された治療アルゴリズムを約束する次世代治療法への注力を強めています。

画期的な生物学的製剤、デジタルケアプラットフォーム、患者中心のプロトコール、そしてホリスティックなアプローチが乾癬治療の連続性をどのように再定義しているか

特定の免疫経路を標的とする画期的な生物学的製剤は、精密治療の新時代を切り開き、これまで中等度から重度の疾患で苦しんでいた患者に救済をもたらしました。同時に、デジタルケアプラットフォームは、遠隔医療相談、症状進行の遠隔モニタリング、アドヒアランスの追跡を通じて、患者がより効果的に治療計画に関与することを可能にしています。ウェアラブルセンサーとモバイルアプリケーションを統合した患者中心のプロトコルは、患者と医療提供者間の協力を促進することで、転帰の改善に寄与しています。

2025年に提案された関税が乾癬治療のサプライチェーン、価格戦略、患者アクセスに及ぼす遠大な影響の評価

2025年に提案された輸入医薬品原薬と乾癬治療の完成品に対する関税は、グローバルサプライチェーンに圧力をかける構えです。製造業者は中核となる生物学的製剤成分のコスト上昇に直面し、生産拠点の戦略的再評価につながる可能性があります。その結果、潜在的な関税関連のコスト上昇へのリスクを軽減するために、国内製造や代替調達戦略への投資を加速させる企業も出てくる可能性があります。

治療の意思決定を促す薬剤モダリティ、投与経路、疾患バリエーション、治療環境、流通チャネルにまたがる患者と医療提供者のセグメントを明らかにします

乾癬治療の状況は、患者や医療従事者の微妙な行動を明らかにする複数のセグメンテーションレンズを通して理解するのが最善です。薬剤タイプを検討する場合、全身治療には生物学的製剤、経口薬、光線療法が含まれ、外用薬にはカルシニューリン阻害薬、コルチコステロイド、レチノイド、ビタミンD類似物質が含まれます。生物学的製剤の中でも、IL-17阻害剤、IL-23阻害剤、T細胞阻害剤、TNF-α阻害剤などの標的クラスは、作用機序や安全性プロファイルが差別化されています。このようなきめ細かさにより、利害関係者は、満たされていない免疫学的ニーズと臨床開発パイプラインを一致させることができます。

乾癬治療のアクセシビリティとイノベーションに影響を与える南北アメリカ、中東・アフリカ、アジア太平洋のユニークなダイナミクスを探る

グローバル市場における乾癬治療のアクセシビリティとイノベーションを形成する上で、地域力学は極めて重要な役割を果たしています。南北アメリカでは、償還の枠組みや官民のパートナーシップが先進的な生物学的製剤の急速な普及を促進し、患者支援サービスを促進する強固な専門薬局ネットワークに支えられています。一方、各州における規制の調和に向けた取り組みは、新規治療薬の市場投入までの時間を短縮しています。

乾癬市場を形成する主要バイオ医薬品・専門企業の戦略的イニシアチブ、調査パートナーシップ、製品イノベーションの分析

主要なバイオ医薬品および専門企業は、乾癬領域における競争力を維持するために様々な戦略的イニシアチブを展開しています。バイオベンチャーのパイオニアは、次世代のIL-17阻害剤とIL-23阻害剤を後期臨床試験まで進めており、一方、世界的な製薬企業は、細胞内シグナル伝達経路を調節するように設計された薬剤で経口低分子化合物ポートフォリオを拡大しています。同時に、専門メーカーは、新規デリバリーシステムと皮膚忍容性の向上により患者のアドヒアランスを改善する、再製剤化された局所療法に投資しています。

乾癬治療の成果を高めるための革新的な薬剤開発、患者との連携、弾力的なサプライチェーン戦略の活用

新興国市場の機会を活用するために、業界リーダーは精密免疫学と新規標的経路を活用した革新的な医薬品開発を優先すべきです。デジタルアドヒアランスプラットフォームから遠隔相談サービスまで、患者エンゲージメントツールを早期に統合することで、臨床試験への登録と長期的な治療アドヒアランスが向上します。さらに、二重調達戦略により弾力的なサプライチェーンの枠組みを確立することで、潜在的な関税変動や世界的な混乱に伴うリスクを軽減することができます。

堅牢な乾癬治療に関する知見を提供するために採用された包括的な混合方法論、データソースの統合、分析フレームワークの詳細

本分析で示された包括的な洞察は、厳密な混合方法論に基づくものです。1次調査は、主要オピニオンリーダー、皮膚科専門家、サプライチェーン専門家との詳細なインタビューから構成され、臨床上および業務上の課題に関する生の視点を把握しました。2次調査は、査読付きジャーナル、規制当局への届出書類、独自の業界データベースを統合し、市場動向の三角測量と仮説に基づく調査の検証を行いました。

乾癬治療とケア提供の将来を形作る主要な発見、新たな機会、戦略的重要事項の要約

本エグゼクティブサマリーでは、乾癬治療を再定義する治療法、デジタルエンゲージメント、市場セグメンテーションにおける変革的なシフトを明らかにしました。提案されている関税の戦略的意味合いから、患者のサブタイプや地域ダイナミクスの微妙な差異に至るまで、利害関係者は現在、治療の展望を形成する力について統合された見解を持っています。新たなビジネスチャンスは、ターゲットを絞った生物学的製剤のイノベーション、データ主導型の患者支援プラットフォーム、そして弾力的なサプライチェーンアーキテクチャの交差点にあります。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場力学

• 乾癬治療の結果を最適化するために、遺伝子およびバイオマーカープロファイリングによる個別化医療に焦点を当てる
• 中等度から重度の乾癬の治療プロトコルにおけるIL-17およびIL-23阻害生物製剤の採用が増加
• 遠隔乾癬管理のためのデジタルヘルスプラットフォームと遠隔皮膚科の統合の拡大
• バイオシミラー生物製剤の出現によりコスト競合が促進され、乾癬治療への患者アクセスが拡大
• 注射剤に代わるチロシンキナーゼを標的とした経口小分子阻害剤の開発
• 慢性乾癬治療の遵守率向上を目的としたモバイルアプリを活用した患者中心のサポートプログラムの導入
• 乾癬における薬剤浸透を高め、全身的副作用を軽減する局所ナノ製剤の進歩
• 難治性症例の有効性を高めるため、生物学的製剤と光線療法を組み合わせた併用療法レジメンの拡大
• 軽度から中等度の乾癬に対する新規PDE4阻害剤の規制承認により、新たな非生物学的選択肢が提供
• 乾癬治療の長期安全性と費用対効果を評価するためのリアルワールドエビデンス研究の強化

第6章 市場洞察

• ポーターのファイブフォース分析
• PESTEL分析

第7章 米国の関税の累積的な影響、2025年

第8章 乾癬治療市場：薬剤タイプ別

• 全身治療
  • 生物学的製剤
    • IL-17阻害剤
    • IL-23阻害剤
    • T細胞阻害剤
    • TNF-α阻害剤
  • 経口薬
  • 光線療法
• 局所治療
  • カルシニューリン阻害剤
  • コルチコステロイド
  • レチノイド
  • ビタミンD類似体

第9章 乾癬治療市場：投与経路別

• 注射剤
• 経口
• 局所

第10章 乾癬治療市場：疾患タイプ別

• 紅皮症性乾癬
• 滴状乾癬
• 逆乾癬
• 尋常性乾癬
• 膿疱性乾癬

第11章 乾癬治療市場：エンドユーザー別

• 外来手術センター（ASC）
• 在宅ケア設定
• 病院
• 専門クリニック

第12章 乾癬治療市場：流通チャネル別

• オフライン
  • 病院薬局
  • 小売薬局
• オンライン

第13章 南北アメリカの乾癬治療市場

• 米国
• カナダ
• メキシコ
• ブラジル
• アルゼンチン

第14章 欧州、中東・アフリカの乾癬治療市場

• 英国
• ドイツ
• フランス
• ロシア
• イタリア
• スペイン
• アラブ首長国連邦
• サウジアラビア
• 南アフリカ
• デンマーク
• オランダ
• カタール
• フィンランド
• スウェーデン
• ナイジェリア
• エジプト
• トルコ
• イスラエル
• ノルウェー
• ポーランド
• スイス

第15章 アジア太平洋の乾癬治療市場

• 中国
• インド
• 日本
• オーストラリア
• 韓国
• インドネシア
• タイ
• フィリピン
• マレーシア
• シンガポール
• ベトナム
• 台湾

第16章 競合情勢

• 市場シェア分析、2024年
• FPNVポジショニングマトリックス、2024年
• 競合分析
  • AbbVie Inc.
  • Almirall, S.A.
  • Amgen Inc.
  • Bausch Health Companies Inc.
  • Biogen Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celltrion, Inc.
  • Eli Lilly and Company
  • Fresenius Kabi AG
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • LEO Pharma A/S
  • Lupin Limited
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • UCB S.A.
  • Viatris Inc.

第17章 リサーチAI

第18章 リサーチ統計

第19章 リサーチコンタクト

第20章 リサーチ記事

第21章 付録

LIST OF FIGURES

• FIGURE 1. PSORIASIS TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. GLOBAL PSORIASIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 3. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 4. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
• FIGURE 6. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
• FIGURE 8. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
• FIGURE 10. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
• FIGURE 12. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
• FIGURE 14. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 15. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 16. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 17. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 18. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 21. ASIA-PACIFIC PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 22. ASIA-PACIFIC PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 23. PSORIASIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 24. PSORIASIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
• FIGURE 25. PSORIASIS TREATMENT MARKET: RESEARCHAI
• FIGURE 26. PSORIASIS TREATMENT MARKET: RESEARCHSTATISTICS
• FIGURE 27. PSORIASIS TREATMENT MARKET: RESEARCHCONTACTS
• FIGURE 28. PSORIASIS TREATMENT MARKET: RESEARCHARTICLES

LIST OF TABLES

• TABLE 1. PSORIASIS TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL PSORIASIS TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL PSORIASIS TREATMENT MARKET SIZE, 2025-2030 (USD MILLION)
• TABLE 5. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 7. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 9. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 11. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 13. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 15. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY IL-17 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY IL-17 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 17. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY IL-23 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY IL-23 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 19. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY T-CELL INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY T-CELL INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 21. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY TNF-ALPHA INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY TNF-ALPHA INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 23. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
• TABLE 25. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 27. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY PHOTOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY PHOTOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
• TABLE 29. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
• TABLE 31. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 33. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 35. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 37. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY RETINOIDS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY RETINOIDS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 39. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY VITAMIN D ANALOGUES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY VITAMIN D ANALOGUES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 41. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
• TABLE 43. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 45. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 47. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
• TABLE 49. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
• TABLE 51. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 53. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ERYTHRODERMIC PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ERYTHRODERMIC PSORIASIS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 55. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY GUTTATE PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY GUTTATE PSORIASIS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 57. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY INVERSE PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY INVERSE PSORIASIS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 59. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY PLAQUE PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY PLAQUE PSORIASIS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 61. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY PUSTULAR PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY PUSTULAR PSORIASIS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 63. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 65. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS (ASCS), BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS (ASCS), BY REGION, 2025-2030 (USD MILLION)
• TABLE 67. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 69. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 71. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 73. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 75. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 77. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 79. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 81. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 83. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 85. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 86. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 87. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
• TABLE 88. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
• TABLE 89. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 90. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
• TABLE 91. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
• TABLE 92. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
• TABLE 93. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 94. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 95. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 96. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 97. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 98. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 99. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 100. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 101. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 102. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 103. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 104. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 105. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 106. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 107. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
• TABLE 108. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
• TABLE 109. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 110. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
• TABLE 111. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
• TABLE 112. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
• TABLE 113. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 114. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 115. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 116. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 117. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 118. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 119. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 120. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 121. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 122. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 123. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
• TABLE 124. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
• TABLE 125. CANADA PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 126. CANADA PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 127. CANADA PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
• TABLE 128. CANADA PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
• TABLE 129. CANADA PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 130. CANADA PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
• TABLE 131. CANADA PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
• TABLE 132. CANADA PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
• TABLE 133. CANADA PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 134. CANADA PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 135. CANADA PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 136. CANADA PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 137. CANADA PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 138. CANADA PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 139. CANADA PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 140. CANADA PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 141. CANADA PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 142. CANADA PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 143. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 144. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 145. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
• TABLE 146. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
• TABLE 147. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 148. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
• TABLE 149. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
• TABLE 150. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
• TABLE 151. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 152. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 153. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 154. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 155. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 156. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 157. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 158. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 159. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 160. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 161. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 162. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 163. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
• TABLE 164. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
• TABLE 165. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 166. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
• TABLE 167. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
• TABLE 168. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
• TABLE 169. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 170. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 171. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 172. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 173. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 174. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 175. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 176. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 177. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 178. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 179. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 180. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 181. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
• TABLE 182. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
• TABLE 183. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 184. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
• TABLE 185. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
• TABLE 186. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
• TABLE 187. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 188. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 189. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 190. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 191. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 192. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 193. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 194. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 195. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 196. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 197. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 198. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 199. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
• TABLE 200. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
• TABLE 201. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 202. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
• TABLE 205. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 206. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 207. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 208. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 209. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 210. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 211. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 212. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 213. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 214. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 215. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 216. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 217. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 218. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 219. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
• TABLE 220. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
• TABLE 221. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 222. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
• TABLE 223. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
• TABLE 224. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
• TABLE 225. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 226. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 227. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 228. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 229. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 230. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 232. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 234. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 235. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 236. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 237. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
• TABLE 238. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
• TABLE 239. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 240. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
• TABLE 241. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
• TABLE 242. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
• TABLE 243. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 244. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 245. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 246. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 247. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 248. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 249. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 250. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 251. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 252. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 253. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 254. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 255. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
• TABLE 256. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
• TABLE 257. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 258. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
• TABLE 259. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
• TABLE 260. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
• TABLE 261. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 262. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 263. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 264. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 265. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 266. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 267. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 268. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 269. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 270. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 271. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 272. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 273. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
• TABLE 274. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
• TABLE 275. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 276. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
• TABLE 277. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
• TABLE 278. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
• TABLE 279. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 280. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 281. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 282. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 283. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 284. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 285. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 286. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 287. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 288. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 289. ITALY PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 290. ITALY PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 291. ITALY PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
• TABLE 292. ITALY PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
• TABLE 293. ITALY PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 294. ITALY PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
• TABLE 295. ITALY PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
• TABLE 296. ITALY PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
• TABLE 297. ITALY PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 298. ITALY PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 299. ITALY PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 300. ITALY PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 301. ITALY PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 302. ITALY PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 303. ITALY PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 304. ITALY PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 305. ITALY PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 306. ITALY PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 307. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 308. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 309. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
• TABLE 310. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
• TABLE 311. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 312. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
• TABLE 313. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
• TABLE 314. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
• TABLE 315. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 316. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 317. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 318. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 319. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 320. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 321. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 322. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 323. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 324. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 325. UNITED ARAB EMIRATES PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 326. UNITED ARAB EMIRATES PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 327. UNITED ARAB EMIRATES PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
• TABLE 328. UNITED ARAB EMIRATES PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
• TABLE 329. UNITED ARAB EMIRATES PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 330. UNITED ARAB EMIRATES PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
• TABLE 331. UNITED ARAB EMIRATES PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
• TABLE 332. UNITED ARAB EMIRATES PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
• TABLE 333. UNITED ARAB EMIRATES PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 334. UNITED ARAB EMIRATES PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 335. UNI

The Psoriasis Treatment Market was valued at USD 19.54 billion in 2024 and is projected to grow to USD 21.19 billion in 2025, with a CAGR of 8.71%, reaching USD 32.26 billion by 2030.

Understanding the Psoriasis Treatment Paradigm Amid Evolving Therapeutic Options and Regulatory Dynamics Shaping Patient Outcomes

Understanding the complexities of psoriasis treatment is essential as evolving therapeutic platforms and regulatory frameworks reshape patient care worldwide. Chronic in nature, psoriasis imposes substantial physical discomfort and psychosocial burdens, prompting an urgent need for more effective, targeted interventions. In response, pharmaceutical and biotechnology innovators have intensified their focus on next-generation modalities that promise enhanced efficacy, improved safety profiles, and personalized treatment algorithms.

Moreover, intricate reimbursement landscapes and heightened patient expectations are driving stakeholders to reassess traditional care paradigms. Health systems seek integrated approaches that balance clinical outcomes with cost containment, while patients demand modalities that align with their lifestyles and long-term wellness goals. Consequently, a nuanced understanding of current market dynamics lays the foundation for stakeholders to identify areas of unmet need, anticipate regulatory shifts, and craft strategies that deliver sustainable value in the psoriasis treatment continuum.

How Breakthrough Biologics, Digital Care Platforms, Patient-Centric Protocols, and Holistic Approaches Are Redefining the Psoriasis Care Continuum

Breakthrough biologics targeting specific immune pathways have ushered in a new era of precision therapy, offering relief for patients who previously struggled with moderate to severe disease. At the same time, digital care platforms are empowering individuals to engage with treatment plans more effectively through telemedicine consultations, remote monitoring of symptom progression, and adherence tracking. Patient-centric protocols, which integrate wearable sensors and mobile applications, contribute to improved outcomes by fostering collaboration between patients and providers.

Meanwhile, holistic approaches that consider comorbidities such as arthritis, cardiovascular conditions, and mental health are gaining traction, ensuring that treatment regimens address the multifaceted nature of the disease. Consequently, the convergence of targeted biologics, advanced digital tools, and comprehensive clinical frameworks is redefining the psoriasis care continuum, setting new standards for efficacy, convenience, and long-term disease management.

Assessing the Far-Reaching Effects of Proposed 2025 Tariff Structures on Psoriasis Therapies Supply Chains, Pricing Strategies, and Patient Access

In 2025, proposed tariffs on imported active pharmaceutical ingredients and finished psoriasis therapies are poised to exert pressure on global supply chains. Manufacturers may face increased costs for core biologic components, leading to strategic reevaluations of production footprints. Consequently, some organizations could accelerate investments in domestic manufacturing or alternative sourcing strategies to mitigate exposure to potential tariff-related cost increases.

Furthermore, pricing strategies will likely evolve as payers and providers negotiate contracts that reflect shifting cost structures. In parallel, patient access programs and co-pay assistance initiatives may expand to preserve adherence among individuals reliant on costly biologics. Therefore, understanding the cumulative implications of these tariff proposals is critical for companies aiming to safeguard supply continuity, optimize pricing models, and maintain equitable access for the psoriasis patient population.

Uncovering Distinct Patient and Provider Segments Across Drug Modalities, Administration Routes, Disease Variants, Care Settings, and Distribution Channels Driving Treatment Decisions

The psoriasis treatment landscape is best understood through multiple segmentation lenses that illuminate nuanced patient and provider behaviors. When examining drug type, systemic treatments encompass biologics, oral medications, and phototherapy, while topical applications include calcineurin inhibitors, corticosteroids, retinoids, and vitamin D analogues. Within biologics, targeted classes such as IL-17 inhibitors, IL-23 inhibitors, T-cell inhibitors, and TNF-alpha inhibitors offer differentiated mechanisms of action and safety profiles. This granularity enables stakeholders to align clinical development pipelines with unmet immunological needs.

Analysis of administration routes reveals critical trade-offs between injectable, oral, and topical therapies. Injectable formulations often deliver potent systemic control but have higher complexity in patient administration and monitoring. Orally administered agents confer ease of use but must address first-pass metabolism and potential drug-drug interactions. Topical therapies remain fundamental for localized disease management, demanding formulations that optimize skin penetration and minimize irritation.

Disease type segmentation further sharpens market understanding by distinguishing between erythrodermic psoriasis, guttate psoriasis, inverse psoriasis, plaque psoriasis, and pustular psoriasis. Each subtype presents unique clinical manifestations, necessitating tailored therapeutic approaches and clinical trial designs. Additionally, end-user environments ranging from ambulatory surgical centers and homecare settings to hospitals and specialty clinics dictate distinct service delivery models and reimbursement considerations. Finally, distribution channel insights differentiate between offline pathways-hospital pharmacies and retail pharmacies-and online platforms, shaping omnichannel strategies that maximize patient reach and supply chain efficiency.

Exploring Unique Dynamics in the Americas, Europe Middle East & Africa, and Asia-Pacific Regions Influencing Psoriasis Treatment Accessibility and Innovation

Regional dynamics play a pivotal role in shaping psoriasis treatment accessibility and innovation across global markets. In the Americas, reimbursement frameworks and private-public partnerships have fostered rapid adoption of advanced biologics, supported by robust specialty pharmacy networks that facilitate patient support services. Meanwhile regulatory harmonization efforts across states are reducing time to market for novel therapies.

In Europe, Middle East & Africa, market heterogeneity is pronounced, with Western European nations benefiting from streamlined approval pathways and patient registries, while emerging economies in the Middle East and Africa face challenges related to infrastructure, diagnostic capacity, and healthcare funding. However, public health initiatives and international collaborations are gradually expanding access to both systemic and topical treatments, laying the groundwork for future growth.

Within Asia-Pacific, dynamic innovation hubs are emerging alongside established markets. Japan and Australia continue to invest heavily in biologic research and development, whereas Southeast Asian countries are rapidly scaling generic and biosimilar production to enhance affordability. Across the region, digital health adoption is accelerating, enabling remote patient monitoring and education programs that bridge gaps in specialist care delivery.

Analyzing Strategic Initiatives, Research Partnerships, and Product Innovations from Leading Biotech and Specialty Firms Shaping the Psoriasis Market

Leading biopharmaceutical and specialty firms are deploying a variety of strategic initiatives to maintain competitive positioning within the psoriasis arena. Biotech pioneers are advancing next-generation IL-17 and IL-23 inhibitors through late-stage clinical trials, while global pharmaceutical companies are expanding their oral small molecule portfolios with agents designed to modulate intracellular signaling pathways. Concurrently, specialty manufacturers are investing in reformulated topical therapies that improve patient adherence through novel delivery systems and enhanced skin tolerability.

Research partnerships between industry leaders and academic centers are accelerating the translation of biomarker discoveries into therapeutic candidates, particularly in the area of personalized medicine. Meanwhile, collaborations with contract manufacturing organizations are enabling scalable biologics production, thereby reducing time to market and enhancing supply chain resilience. In addition, strategic acquisitions and licensing deals are broadening product pipelines, ensuring that companies can address the full spectrum of disease severity and subtype variations.

Leveraging Innovative Drug Development, Collaborative Patient Engagement, and Resilient Supply Chain Strategies to Enhance Psoriasis Care Outcomes

To capitalize on evolving market opportunities, industry leaders should prioritize innovative drug development that leverages precision immunology and novel target pathways. Early integration of patient engagement tools-ranging from digital adherence platforms to remote consultation services-will enhance clinical trial enrollment and long-term treatment adherence. Additionally, establishing resilient supply chain frameworks with dual sourcing strategies can mitigate risks associated with potential tariff fluctuations and global disruptions.

Furthermore, forging multi-stakeholder collaborations with payers, patient advocacy groups, and regulatory bodies can streamline approval processes and foster transparent pricing dialogues. Investing in real-world evidence generation will also provide a stronger evidentiary basis for demonstrating long-term value, ultimately facilitating formulary inclusion and reimbursement approval. By embedding these recommendations within core strategic plans, companies can achieve sustainable growth and deliver superior patient outcomes in the psoriasis treatment landscape.

Detailing the Comprehensive Mixed-Methods Approach, Data Sources Integration, and Analytical Frameworks Employed to Deliver Robust Psoriasis Treatment Insights

A rigorous mixed-methods approach underpins the comprehensive insights presented in this analysis. Primary research consisted of in-depth interviews with key opinion leaders, dermatology specialists, and supply chain experts to capture firsthand perspectives on clinical and operational challenges. Secondary research integrated peer-reviewed journals, regulatory filings, and proprietary industry databases to triangulate market trends and validate hypothesis-driven inquiries.

Quantitative data was subjected to statistical validation techniques, ensuring the reliability of segmentation and regional models. Qualitative insights were coded thematically to uncover emerging patterns in therapeutic adoption, patient behavior, and competitive dynamics. Finally, synthesis workshops with cross-functional teams refined the analytical frameworks and stress-tested strategic scenarios. This multi-layered methodology ensures that the findings are both robust and actionable for decision-makers across the psoriasis treatment ecosystem.

Summarizing Key Findings, Emerging Opportunities, and Strategic Imperatives That Will Shape the Future of Psoriasis Treatment and Care Delivery

This executive summary has illuminated transformative shifts in therapeutic modalities, digital engagement, and market segmentation that are redefining psoriasis care. From the strategic implications of proposed tariffs to the nuanced differentiation of patient subtypes and regional dynamics, stakeholders now have a consolidated view of the forces shaping the treatment landscape. Emerging opportunities lie at the intersection of targeted biologic innovation, data-driven patient support platforms, and resilient supply chain architectures.

In closing, strategic imperatives include prioritizing precision medicine approaches, deepening cross-sector collaborations, and continuously adapting to regulatory evolutions. By aligning scientific breakthroughs with patient-centric delivery models and robust commercial frameworks, organizations can secure competitive advantage and advance the standard of care for individuals living with psoriasis.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Market Sizing & Forecasting

5. Market Dynamics

• 5.1. Focus on personalized medicine through genetic and biomarker profiling to optimize psoriasis treatment outcomes
• 5.2. Growing uptake of IL-17 and IL-23 inhibitor biologics in treatment protocols for moderate to severe psoriasis
• 5.3. Increasing integration of digital health platforms and teledermatology for remote psoriasis management
• 5.4. Emergence of biosimilar biologics driving cost competition and expanded patient access to psoriasis therapies
• 5.5. Development of oral small molecule inhibitors targeting tyrosine kinases as alternative to injectable treatments
• 5.6. Implementation of patient-centric support programs leveraging mobile apps to improve adherence in chronic psoriasis care
• 5.7. Advancements in topical nanoformulations to enhance drug penetration and reduce systemic side effects in psoriasis
• 5.8. Expansion of combination therapy regimens combining biologics with phototherapy for enhanced efficacy in refractory cases
• 5.9. Regulatory approval of novel PDE4 inhibitors for mild to moderate psoriasis offering new non-biologic options
• 5.10. Heightened emphasis on real world evidence studies to assess long-term safety and cost effectiveness of psoriasis drugs

6. Market Insights

• 6.1. Porter's Five Forces Analysis
• 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Psoriasis Treatment Market, by Drug Type

• 8.1. Introduction
• 8.2. Systemic Treatments
  • 8.2.1. Biologics
    • 8.2.1.1. IL-17 Inhibitors
    • 8.2.1.2. IL-23 Inhibitors
    • 8.2.1.3. T-cell Inhibitors
    • 8.2.1.4. TNF-alpha Inhibitors
  • 8.2.2. Oral Medications
  • 8.2.3. Phototherapy
• 8.3. Topical Treatments
  • 8.3.1. Calcineurin Inhibitors
  • 8.3.2. Corticosteroids
  • 8.3.3. Retinoids
  • 8.3.4. Vitamin D Analogues

9. Psoriasis Treatment Market, by Route of Administration

• 9.1. Introduction
• 9.2. Injectable
• 9.3. Oral
• 9.4. Topical

10. Psoriasis Treatment Market, by Disease Type

• 10.1. Introduction
• 10.2. Erythrodermic Psoriasis
• 10.3. Guttate Psoriasis
• 10.4. Inverse Psoriasis
• 10.5. Plaque Psoriasis
• 10.6. Pustular Psoriasis

11. Psoriasis Treatment Market, by End-User

• 11.1. Introduction
• 11.2. Ambulatory Surgical Centers (ASCs)
• 11.3. Homecare Settings
• 11.4. Hospitals
• 11.5. Specialty Clinics

12. Psoriasis Treatment Market, by Distribution Channel

• 12.1. Introduction
• 12.2. Offline
  • 12.2.1. Hospital Pharmacies
  • 12.2.2. Retail Pharmacies
• 12.3. Online

13. Americas Psoriasis Treatment Market

• 13.1. Introduction
• 13.2. United States
• 13.3. Canada
• 13.4. Mexico
• 13.5. Brazil
• 13.6. Argentina

14. Europe, Middle East & Africa Psoriasis Treatment Market

• 14.1. Introduction
• 14.2. United Kingdom
• 14.3. Germany
• 14.4. France
• 14.5. Russia
• 14.6. Italy
• 14.7. Spain
• 14.8. United Arab Emirates
• 14.9. Saudi Arabia
• 14.10. South Africa
• 14.11. Denmark
• 14.12. Netherlands
• 14.13. Qatar
• 14.14. Finland
• 14.15. Sweden
• 14.16. Nigeria
• 14.17. Egypt
• 14.18. Turkey
• 14.19. Israel
• 14.20. Norway
• 14.21. Poland
• 14.22. Switzerland

15. Asia-Pacific Psoriasis Treatment Market

• 15.1. Introduction
• 15.2. China
• 15.3. India
• 15.4. Japan
• 15.5. Australia
• 15.6. South Korea
• 15.7. Indonesia
• 15.8. Thailand
• 15.9. Philippines
• 15.10. Malaysia
• 15.11. Singapore
• 15.12. Vietnam
• 15.13. Taiwan

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. AbbVie Inc.
  • 16.3.2. Almirall, S.A.
  • 16.3.3. Amgen Inc.
  • 16.3.4. Bausch Health Companies Inc.
  • 16.3.5. Biogen Inc.
  • 16.3.6. Boehringer Ingelheim GmbH
  • 16.3.7. Bristol-Myers Squibb Company
  • 16.3.8. Celltrion, Inc.
  • 16.3.9. Eli Lilly and Company
  • 16.3.10. Fresenius Kabi AG
  • 16.3.11. GlaxoSmithKline plc
  • 16.3.12. Johnson & Johnson Services, Inc.
  • 16.3.13. LEO Pharma A/S
  • 16.3.14. Lupin Limited
  • 16.3.15. Merck & Co., Inc.
  • 16.3.16. Mitsubishi Tanabe Pharma Corporation
  • 16.3.17. Novartis AG
  • 16.3.18. Pfizer Inc.
  • 16.3.19. Samsung Bioepis Co., Ltd.
  • 16.3.20. Sanofi S.A.
  • 16.3.21. Sun Pharmaceutical Industries Ltd.
  • 16.3.22. Takeda Pharmaceutical Company Limited
  • 16.3.23. UCB S.A.
  • 16.3.24. Viatris Inc.

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix